Key result
Off-pump transapical mitral valve repair using the NeoChord DS1000 system in 10 high-risk patients with severe degenerative mitral regurgitation resulted in 0% 6-week mortality and reduced MR to mild or less in 7 patients.
Why the study?
The authors sought to describe imaging and clinical outcomes using the innovative NeoChord DS1000 device platform for transapical mitral valve repair without cardiopulmonary bypass.
Does the NeoChord DS1000 system reduce mitral regurgitation and improve left ventricular dimensions in moderate to high-risk patients with degenerative mitral valve regurgitation?
Observational (n=10)
No
Does the NeoChord DS1000 system reduce mitral regurgitation and improve left ventricular dimensions in moderate to high-risk patients with degenerative mitral valve regurgitation?
The NeoChord DS1000 system is a feasible and safe minimally invasive option that effectively reduces mitral regurgitation and improves left ventricular dimensions in select high-risk patients with degenerative mitral valve regurgitation.
No takes yet. Share an insight, caveat, or question.
May inform high-risk degenerative MR options; leaves open need for prospective validation.
Brown et al. (2023) conducted an observational in Degenerative mitral valve regurgitation (n=10). NeoChord DS1000 system was evaluated on 30-day and 6-week mortality and readmission. Off-pump transapical mitral valve repair using the NeoChord DS1000 system in 10 high-risk patients with severe degenerative mitral regurgitation resulted in 0% 6-week mortality and reduced MR to mild or less in 7 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: